1
. Cytokines can have either pro-or anti-inflammatory activity and immunosuppressive activity, depending on the microenvironment. Immune cells are the major source of cytokines but many human cells are capable of producing them 1, 2 (Table 1 ) and, importantly, their production acts as a means of communication between both cells and tissues.
In this Perspective we discuss the role of cytokines in causing symptoms that affect quality of life in people with cancer and the possible influence of cytokines on cancer outcome.
Cytokines and cancer development
Under normal conditions, an inflammatory response (bOX 1) is regulated by active mechanisms. Anti-inflammatory cytokines, such as interleukin 10 (IL10) and transforming growth factor β (TGFβ), are important in this process, as are soluble receptors that neutralize the activity of cytokines, such as soluble IL1 receptor type II (IL1R2), and cytokine receptor antagonists, such as IL1RA. Although often overlooked, neuronal pathways and hormones (such as cortisol and adrenaline) 3, 4 also affect the immune response. Adrenal production of cortisol, a potent anti-inflammatory glucocorticoid hormone, is regulated by the hypothalamic-pituitary-adrenal (HPA) axis 5 . Disrupted HPA signalling resulting in altered release of glucocorticoid hormones, or disrupted glucocorticoid receptor function, might sustain inflammation. A disturbed balance between pro-and antiinflammatory mechanisms leads to chronic immune activation and inflammation 6 , as occurs often in people with cancer.
Clinical studies. Clinical and epidemiological studies have suggested a strong association between chronic local inflammation and some types of cancer 7 , with inflammation often occurring in and around tumours 8 . Prehn first reported in 1972 that immune cells promote tumour growth in an animal model 9 , and it is now established that the tumour stroma includes inflammatory cells, such as M2 macrophages, dendritic cells and T-regulatory lymphocytes 10 (bOX 1), that promote development and progression of cancer [10] [11] [12] (FIG. 1) .
The tumour microenvironment is rich in cytokines and other inflammatory mediators that influence immunosuppression, growth of cancer cells, tissue remodelling and angiogenesis [13] [14] [15] (FIG. 1) . Immunosuppressive networks mediated by IL10 and TGFβ seem to inhibit cell-mediated immune responses against cancer cells 16 . Moreover, the function of circulating T cells is often impaired in cancer 17 . Clinical data show a decreased ratio of circulating T helper 1 (T H 1) cells to circulating T H 2 cells and their associated cytokines in different cancer types and in effected by the cancer itself and by different treatments. Some cytokines, including interferon α (IFNα) and IL2, have been used in cancer treatment, and their ability to cause fatigue, depression and other symptoms is well-described [52] [53] [54] . Release of cytokines may mediate both the organ-confined and the systemic toxic symptoms that are associated with different types of cancer treatment such as radiation therapy, chemotherapy and hormonal therapy (FIG. 3) .
Radiation therapy can lead to release of cytokines in various tissues, and cytokines are associated with the development of late radiation damage that can occur in irradiated normal tissues months or years after treatment 55 . TGFβ has a crucial role in the initiation, development and persistence of radiation-induced fibrosis 56 , and circulating levels of TGFβ1 predict radiation-induced lung damage 57 . The TGFβ1 (-509 T) allele is associated with increased circulating levels of TGFβ1 (ReF. 58) and radiation-induced damage in normal tissues in women with early breast cancer [59] [60] [61] or gynaecological cancers 62 . Combined analysis of two studies of women with breast cancer showed that the 8% of patients who were homozygous for the TGFβ1 (-509 T) variant allele had a 15-fold increase in risk of fibrosis following radiotherapy 61 (Table 3) . Cytokines might also have systemic effects after radiation treatment. Evidence from animal models suggests that local irradiation of a tumour can result in regression of distant nonirradiated tumours, an effect that is mediated by T cells 63 following systemic activation of the immune system 64 . Chemotherapy is also known to have direct and indirect effects on the immune system. Chemotherapy-induced death of cancer cells can cause the release of immunogenic antigens, which result in a cell-mediated immune response to the tumour, as recently reviewed 65 by Zitvogel et al. Cytokine secretion induced by chemotherapeutic drugs might also mediate the development of other side effects, including psychobehavioural effects, during and after treatment (FIG. 3) . Paclitaxel can mimic the effects of lipopolysaccharide (LPS), which is a ligand for Toll-like receptor 4 (TLR4) expressed on innate immune cells. Exposure of murine macrophages to paclitaxel led to the increased release of both tumour necrosis factor α (TNFα) and IL1β [66] [67] [68] . Furthermore, paclitaxel can induce expression of the pro-inflammatory cytokine IL8 in lung carcinoma cell lines 69 . Treatment with paclitaxel or docetaxel was reported to increase the expression of IL2, (pro-inflammatory)   IL1, IL2, IL4, IL6, IL7, IL10, IL11, IL12 IL15, IL16, IL17, IL18, IL21, IL23,  TNFα, TNFβ, IFNα, IFNβ, IFNγ   Humoral immunity  (pro-inflammatory)   IL1, IL2, IL4, IL5, IL6, IL10, IL12, IL13, IL15, IL21, IL25, TGFβ   Allergic immunity  (pro-inflammatory)   IL3, IL4, IL5, IL9, IL13, IL25, IFNγ, GM-CSF, SCF   Anti-inflammatory  IL4, IL5, IL6, IL10, IL13, IL19, IL20, IL22, IL24, IL26, TGFβ, IL1RA,  signalling by IL1RII Pro-inflammatory cytokines stimulate cell-mediated, humoral and/or allergic immunity. The major cytokine mediating cell-mediated immunity is interferon-γ (IFNγ Increased levels of circulating cytokines and their receptors (most often of the proinflammatory cytokine IL6) have been found in observational studies of patients with various types of cancer, both at diagnosis of the primary disease and in those with metastases, compared with healthy people and people with benign tumours [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] ( Table 2 ). There have been few studies of circulating levels of cytokines in people after primary treatment of cancer and in cancer survivors. In a longitudinal study of patients with kidney cancer, circulating levels of IL6 and IL10 at diagnosis were higher than in controls with benign kidney disease, and remained significantly higher 3 months after resection of the primary tumour 25 . Preliminary data from our group 29 indicate that circulating levels of several different pro-and anti-inflammatory cytokines are substantially higher in people without active breast or colorectal cancer up to 5 years after diagnosis than in healthy controls.
Polymorphisms. Human genetic variation can modulate the risk of developing a cancer, the risk of developing symptoms related to cancer and its treatment, and the outcome of cancer. The most common variations in the genome are single-nucleotide polymorphisms (SNPs) 30 . In human disease several SNPs in genes encoding cytokines have been associated with variations in the level of transcription and expression, but for many cytokines the data are inconsistent (see Cytokine gene polymorphism in human disease in Further information). In a systematic review of 161 meta-analyses and pooled analyses of SNPs in 99 candidate genes in 18 cancer sites, nearly one-third (98/344) of gene variants were significantly associated with cancer, including 6 cytokine gene variants 31 . Other small studies indicate that SNPs in cytokine genes might be involved in the development of cancer [32] [33] [34] [35] [36] [37] [38] [39] (Table 3) ; however, such results are not always in agreement 40, 41 . Generally, candidate gene studies are considered to be informative but to have limitations, a lack of replication being the main concern in these relatively small studies 42 .
Cytokines and the central nervous system Macrophages in the brain, known as microglial cells, are an important source of proinflammatory cytokines, and are involved in the pathogenesis of various neurological diseases 43 . Furthermore, inflammatory stimuli, including circulating cytokines, can reach the brain by several pathways [44] [45] [46] [47] [48] [49] [50] ( FIG. 2) and stimulate microglial cells to produce pro-inflammatory cytokines and other inflammatory mediators. The best example of the communication between peripheral cytokines and the brain is 'sickness behaviour' , which is induced by peripheral infection and mediated by temporarily expressed pro-inflammatory cytokines in the periphery and in the brain 51 . Similarly, peripherally produced cytokines in cancer may have a role in the development of psychobehavioural symptoms, such as fatigue and cognitive impairment.
Cytokines and symptoms in cancer patients
Cytokines and cancer treatment. The production and release of cytokines can be IL6, IFNγ and granulocyte macrophagecolony stimulating factor (GM-CSF) and decrease the expression of IL1 and TNFα in women with advanced breast cancer who responded to treatment 70 . Adjuvant and neo-adjuvant treatment of women with breast cancer with paclitaxel also increased serum levels of IL6, IL8 and IL10, and these changes correlated with joint pain and flulike symptoms 71 . Another anticancer drug, etoposide, has been reported to stimulate production of IL6 by murine macrophages and to induce sickness-like behaviour in animals 72 . Some drugs may increase production of cytokines by the expansion of the particular pool of immune cells, which is also involved in anticancer mechanisms. For example, treatment with gemcitabine increased the numbers of IFNγ-producing T cells and activated CD69
+ cells in patients with pancreatic cancer 73 . Chemotherapy may also cause organ-confined toxic effects, which are drug-specific and mediated by cytokines. For example, animal models support a role of increased secretion of TNFα in cisplatin-induced nephrotoxicity 74, 75 . Local production of TNFα by renal parenchymal cells promotes damage and is associated with increased circulating and urinary levels of TNFα 76 . Bleomycin has a major role in treatment of testicular tumours and Hodgkin lymphoma but is associated with pulmonary toxicity and occasionally with fatal pulmonary fibrosis 77 . In animal models of bleomycin-induced lung fibrosis, TGFβ1 is a pivotal pro-fibrotic cytokine and other pro-inflammatory cytokines (such as IL1, IL6 and TNFα) also contribute [78] [79] [80] . Aromatase inhibitors, which reduce oestrogen to low levels in the plasma and tissues of postmenopausal women 81 , are used frequently as adjuvant hormonal treatment in postmenopausal women with breast cancer but can cause arthralgia (joint pain) and bone loss, sometimes leading to discontinuation of treatment. In premenopausal women, treatment of cancer can induce premature ovarian failure and significant decreases in oestrogen levels 82 . Various immune cells (such as dendritic cells, macrophages and B cells) express oestrogen receptors and oestrogen can influence their activity 83 . Oestrogen downregulates cellmediated immune responses and promotes humoral immune responses, whereas oestrogen deficiency increases cell-mediated immune responses and the production of pro-inflammatory cytokines such as IL1, IL6 and TNFα 84 . These cytokines might mediate arthralgia during therapy with aromatase inhibitors. Animal models have shown that TNFα secreted under conditions of oestrogen deficiency directly promotes osteoclast activation and bone resorption. TNFα also augments the sensitivity of maturing osteoclasts to the osteoclastogenic factor RANKL (receptor activator of nuclear factor κB (NFκB) ligand), a member of the TNF superfamily that is produced by activated T lymphocytes, bone marrow stromal cells and osteoblasts 85 . Various specific cancer treatments stimulate the immune system to produce pro-inflammatory cytokines that are associated with toxic effects of treatment such as cancer-related fatigue, flu-like systemic effects and bone loss; they can lead to impaired quality of life of patients with cancer and poor compliance with treatment. However, stimulation of the immune system by specific cancer treatments might also have a substantial role in producing anticancer effects. Cancer drugs might differentially effect the secretion of cytokines in humans with cancer, and this secretion might be a tool with which to monitor the therapeutic indices of the drugs in the future.
Cytokines and fatigue, depression and cognitive impairment. Increasing evidence indicates that 30-60% of people with cancer suffer from fatigue, and that a subset of patients (especially women with breast cancer) suffer from cognitive impairment during and after treatment [86] [87] [88] [89] . Fatigue and cognitive decline have a negative impact on quality of life and such symptoms can persist for at least 10 years in some breast cancer survivors 90, 91 . The underlying mechanisms remain poorly understood, making pharmacological interventions difficult. However, there is evidence that supports increased proinflammatory cytokine production as a candidate mechanism for fatigue and cognitive impairment in cancer patients.
Studies in animals have shown that peripheral activation of the immune system by a subseptic dose of LPS (FIG. 2) induced increased expression of pro-inflammatory cytokines in the brain [92] [93] [94] [95] . Circulating LPS and pro-inflammatory cytokines have been shown to disrupt learning and memory in animals [96] [97] [98] [99] , but peripherally administered LPS in IL6-deficient animals did not result in cognitive defects, indicating the probable importance of IL6 in the development of cognitive impairment 100 . IL10 counteracts the production of IL6 by microglial cells 101 , and IL10-deficient animals show increased production of pro-inflammatory cytokines
Box 1 | Role of cytokines in inflammation and immune responses
Innate immunity is a non-specific, short-lasting first line of host defence that depends on cells of myeloid (for example, monocytes, macrophages, dendritic cells, neutrophils and mast cells) and lymphoid (for example, natural killer cells) origin 229 . Various innate and other immune cells express germline-encoded receptors, including Toll-like receptors (TLRs); these receptors recognize a range of exogenous microbial antigens and endogenous ligands, which include nucleic acids and heat shock proteins. When activated, TLRs lead to activation of nuclear factor κB and cytokine production, which mediates the nature and magnitude of adaptive inflammatory responses [230] [231] [232] . Cancer cells can acquire properties characteristic of innate immune cells; they not only produce cytokines but can also express functional TLRs [233] [234] [235] . During an innate immune response macrophages are activated and form a continuum between M1 and M2 macrophages, which produce different cytokines and receptors for cytokines. M1 macrophages stimulate cell-mediated responses through the production of pro-inflammatory cytokines (interleukin 1 (IL1), IL6, IL12, IL23, tumour necrosis factor-α and high levels of signalling IL1 receptor type I (IL1RI)), whereas M2-macrophages stimulate humoral responses, tissue remodelling and angiogenesis through the production of anti-inflammatory cytokines (IL10 and transforming growth factor-β (TGFβ)) and high levels of decoys that antagonize IL1, such as IL1RII and IL1 receptor antagonist 236 . M2 macrophages are found commonly among the host cells that infiltrate most tumours both in the periphery and in the brain that is associated with increased fatigue and motor deficits 102 . Interestingly, increased levels of circulating IL1, TNFα, IL6 and C-reactive protein (CRP) in healthy volunteers challenged by LPS were associated with impaired memory 103 . Increased levels of these cytokines in the elderly have been associated with gradual cognitive decline and development of dementia 104 . Low levels of cytokines and their receptors are produced in the central nervous system (CNS), including areas involved in memory (such as the hippocampus), and animal models have shown that physiological levels of pro-inflammatory cytokines such as IL1 are important for normal memory and neural plasticity 105 .
Higher levels of pro-inflammatory cytokines in the brain are neurotoxic and can induce neurodegenerative disorders in humans 106 . In animals, administration of pro-inflammatory cytokines to the brain was found to cause increased metabolism of neurotransmitters, including noradrenaline, dopamine and serotonin 107, 108 , which are involved in regulation of mood, memory, learning and sleep.
Increased circulating levels of cytokines are known to be associated with cancer (Table 2 ) and the pathways of communication between CNS and the periphery, including the circulatory system and the peripheral nervous system, are wellunderstood (FIG. 2) . However, we have been able to identify only one published clinical study that showed an association between increased circulating levels of cytokines and cognitive impairment. In that study, patients with acute myeloid leukaemia or myelodysplastic syndrome who had higher circulating levels of IL6 at diagnosis were found to have poorer executive function, whereas higher levels of IL8 were associated with better memory 109 . There are no published studies demonstrating a lack of association between cytokines and cognitive impairment, but this may reflect publication bias.
In a quantitative review, a significant correlation between fatigue and circulating levels of IL6 and IL1RA was found in patients with cancer 110 . In breast cancer survivors, persistent fatigue has been associated with increased levels of circulating markers of inflammation including soluble IL6R and IL1RA, increased production of pro-inflammatory cytokines (IL6 and TNFα) by monocytes in response to LPS at rest and in response to experimental challenge, and increased blood levels of CD4 + T cells 111, 112 . Persistent cancer-related fatigue has also been associated with subtle deregulation of the HPA axis with flattened diurnal fluctuation of cortisol levels 113 and blunted cortisol responses to experimental psychological stress 114, 115 . Moreover, a flattened cortisol response during psychological stress was associated with increased production of IL6 by monocytes ex vivo in response to LPS stimulation 115 . Preliminary evidence showing that IL1β -511CC and -511CT genotypes were associated with fatigue in breast cancer survivors 116 (Table 3) suggests that the risk of development of cancer-related fatigue might be predetermined. This is further supported by the finding that flattened diurnal fluctuations in cortisol levels have been reported in some healthy individuals 117, 118 . Decreased cortisol production rather than decreased responsiveness of the cortisol receptor appears to have a crucial role in persistent fatigue 115 . In a large and welldesigned prospective cohort study, psychological distress and fatigue were related to higher risk of recurrence and decreased survival in women after treatment of early breast cancer 119 , although this is in contrast to previous reports 120, 121 . Some studies of patients with advanced cancer have suggested that distress and depression accelerate disease progression and decrease survival [122] [123] [124] , but many studies in this field suffer from methodological limitations. In humans and animals, distress and depression are associated with impaired cellmediated immunity and decreased natural killer (NK)-cell activity 125 . In women with breast and ovarian cancer, high levels of psychological distress induce impairment in NK-cell activity peripherally and in the tumour 126, 127 . The flattened diurnal fluctuations of cortisol have been associated with low peripheral NK-cell activity and with poor clinical outcome in a prospective study of women with advanced breast cancer 128 . Two small clinical studies that examined the use of cytokine antagonists during cancer therapy support a causal role of proinflammatory cytokines in cancer-related fatigue. In a small randomized, controlled trial for cancer patients receiving weekly docetaxel (which is known to induce fatigue) with or without etanercept, a TNFα decoy receptor, patients had significantly less fatigue and could receive higher doses of docetaxel than those who received docetaxel alone 129 . In a prospective study of patients with Castleman disease, which is a lymphoproliferative disorder characterized by increased production of IL6, administration of a monoclonal antibody against IL6R was strongly associated with reduced fatigue 130 . Also, in three randomized, placebo-controlled clinical trials of adalimumab, a monoclonal antibody against TNFα, patients with uncontrolled rheumatoid arthritis receiving adalimumab in combination with methotrexate or other standard therapy had significantly less fatigue than those receiving methotrexate or standard therapy alone 131 .
Brain imaging studies indirectly support an association between cytokines, chemotherapy and cognitive impairment. In a recent study, treatment of patients with hepatitis C using IFNα was associated with impaired cognitive function, which correlated with higher brain activity than healthy controls in the dorsal part of the anterior cingulated cortex during a task of visuospatial attention, as documented by functional magnetic resonance imaging scans 132 . Functional imaging of the brain has shown similar changes in people with cancer who received chemotherapy. For example, 5-10 years after treatment breast cancer survivors who received chemotherapy had higher activity in the lower frontal gyrus, as revealed by functional positron-emission tomography, than breast cancer survivors who were not treated with chemotherapy 133 .
Cytokines and physical activity. There is strong evidence from randomized, controlled trials that aerobic physical activity is able to reduce cancer fatigue 134 , but the underlying mechanisms are unknown. However, there is emerging data indicating that a physically active lifestyle modulates cytokine production and is associated with anti-inflammatory effects. In people with chronic conditions such as obesity, heart failure and metabolic syndromes, which are characterized by increased circulating pro-inflammatory cytokines and other inflammatory markers, intervention studies of chronic physical activity alone or in combination with diet showed reductions in the levels of circulating IL6 and/or TNFα in some [135] [136] [137] [138] but not all studies 139, 140 . Evidence from studies with healthy humans and animals shows that increased of circulating IL6, which is released intermittently from skeletal muscle during periods of intense physical activity, has strong anti-inflammatory effects due to inhibition of TNFα production and induction of IL10 and IL1RA production 141 . However, this mechanism cannot explain the beneficial effect of exercise on fatigue in people with cancer, especially advanced cancer where less intensive physical activity is beneficial. Studies in people who did not have cancer showed that exercise reduces expression of TLR4 by peripheral innate immune cells and is associated with blunted TLR signalling and lower production of IL1β, IL6 and TNFα 142 . Studies in humans and animals suggest that physical activity is important for the health of the brain and causes structural and functional changes. This may occur either directly by induction of central and peripheral growth factors such as insulin-like growth factor 1 (IGF1), brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF, also known as VEGFA) or indirectly by reducing the activity of proinflammatory cytokines that inhibit signalling by these growth factors 143 . These findings further support the involvement of cytokines in cancer-related fatigue, cognitive impairment and the beneficial effects of physical activity.
Cytokines and stress. Cancer poses numerous physical and psychological stresses. Many cancer patients, during both treatment and long-term follow-up, experience psychological distress including anxiety and depression 144 . In animals, stress can activate pro-inflammatory pathways in the brain by activation of microglial cells 145, 146 ( FIG. 2) , and these cells respond in a heightened fashion when exposed to LPS, either centrally in the brain 147 or peripherally 148 . In humans, modulation of the immune system by stress is well-known 149 . Studies of chronic and acute stress in models of human stress showed increased circulating levels of IL6 and TNFα compared with controls [150] [151] [152] . In stress-related neuropsychiatric disorders there is evidence of abnormal glucocorticoid signalling 153 , and this may occur in people with cancer. In general, depressed patients have an activated HPA axis, increased levels of cortisol and increased circulating levels of several pro-inflammatory cytokines, which can further stimulate the HPA axis and cortisol production 154 . In people with depression there is evidence of malfunction of cortisol receptors leading to cytokine-induced cortisol resistance, impaired feedback inhibition of the HPA axis and sustained activation of immune cells 153, 155 . Depression and psychological distress sensitize and enhance inflammatory responses to subsequent stressful events and to challenge with various antigens 149 . In animal models and in vitro studies, several classes of antidepressants have been shown to reduce pretreatment levels of pro-inflammatory cytokines, such as IFNγ and TNFα, and to increase the production of anti-inflammatory cytokines, such as IL10. Indeed, antidepressant treatment can lead to normalization of circulating cytokine production in people with depression 156 . Cancer patients who are clinically depressed have significantly higher levels of circulating IL6 than non-depressed cancer patients or healthy controls 157, 158 . In observational studies of breast cancer survivors several years after diagnosis, cancer-related fatigue was strongly associated with depressed mood 91 , supporting a common underlying mechanism. In cancer patients undergoing cytokine therapy with IL2 or IFNα, depression was related to decreased levels of circulating tryptophan, a precursor of serotonin, and consequently to decreased availability of serotonin in the brain 159 . Indeed, peripheral pro-inflammatory cytokines can induce sickness behaviour and depression in animals by decreasing the availability of serotonin in the brain 160 .
Despite the association between depression and cancer-related fatigue, therapy with the selective serotonin-reuptake inhibitor paroxetine, which increases synaptic levels of serotonin in the brain, has been found to reduce depression but not fatigue in patients with cancer-receiving chemotherapy 161, 162 , 
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suggesting that modulation of serotonin may not be a primary mechanism of fatigue related to cancer. Chronic fatigue might be explained by persistent effects of pro-inflammatory cytokines in the brain and peripheral tissues that are not adequately counterbalanced by anti-inflammatory mechanisms. Cancer-related fatigue, depression and cognitive impairment usually lead to a sedentary lifestyle, resulting in proinflammatory effects and increased cytokine production that may further sustain these disturbing symptoms 142 . Cytokines are challenging candidate factors in psychobehavioural symptoms 163 (fatigue, cognitive impairment and depression) (FIG. 3) that need further research.
Cytokines and anorexia and cachexia.
Anorexia and cachexia occur commonly in patients with some types of cancer such as lung or pancreas, but rarely in those with others such as breast or prostate cancer. Anorexia and cachexia in people with advanced cancer are characterized by breakdown of skeletal muscle and abnormalities in fat and carbohydrate metabolism despite adequate nutritional intake, and are not related simply to burden of disease. Cachectic cancer patients have lower survival rates than patients without significant weight loss 164 . Support for a role for pro-inflammatory cytokines in the induction of cachexia comes from animal studies, with supporting evidence in humans 165, 166 . Increased levels of IL1 in the brain have been associated with anorexia in animals 167 , and pro-inflammatory cytokines may be involved in the development both of anorexia and cachexia and of depression (which frequently coexist) through a common pathway 168 . In particular, TNFα induces proteolysis of skeletal muscle and increased expression of genes that encode enzymes in the ubiquitindependent proteolytic pathway in cancer patients 169 . TNFα also induces uncoupling of mitochondrial respiration and metabolic energy production in animal models 170 . Such molecular changes, including increased activity of muscle ubiquitin proteasome, may be detectable before weight loss 171 , but a small double-blinded, placebo-controlled trial of etanercept did not show benefit in weight, appetite or survival in patients with advanced solid cancers 172 . A possible explanation is the involvement of multiple cytokines in causing the anorexia and cachexia syndrome in cancer patients.
A recent exploratory analysis of the effect of IL1β polymorphisms on cachexia in patients in the United States with advanced gastric cancer suggested a significant association between IL1β (-31 C/T and T/T) genotypes and diminished appetite -the IL1β (+3,954 C/T and T/T) genotypes were associated with greater improvements in weight and survival than the IL1β (+3,954 C/C) genotype, independent of treatment effect 173 . A similar study in Chinese patients with locally advanced gastric cancer showed a converse association between the IL1β (+3,954 T) allele and cachexia 174 (Table 3) .
These conflicting results, which are commonly seen in candidate gene studies, might also be explained by the different genetic backgrounds of Western and Asian populations, the interplay between different genetic polymorphisms of the same cytokine and interactions between different cytokines.
Cytokines and pain. Cytokine activation and deregulation is recognized in a variety of painful disease states. Neuropathic pain in cancer is common, the major causes being some types of anticancer treatment and the direct infiltration of nerves by cancer cells 175 .
In numerous animal studies expression of IL1, IL6 and TNFα is upregulated in peripheral nerves, the spinal cord and in particular regions of the brain after peripheral nerve injury. By contrast, anti-inflammatory cytokines (IL4 and IL10) and neutralizing antibodies against pro-inflammatory cytokines or their receptors promote analgesia 176 . Intrathecal injection of IL1RA or of a vector incorporating IL10 decreased production of pro-inflammatory cytokines in the spinal cord and attenuated neuropathic pain 177, 178 . In a study of patients with a variety of pain-associated peripheral neuro pathies, levels of circulating pro-inflammatory and anti-inflammatory cytokines were significantly increased and decreased, respectively, compared with patients with painless neuropathies or healthy controls 179 . Shifting the balance from pro-to anti-inflammatory cytokines is a promising approach to management of neuropathic cancer pain.
The release of pro-inflammatory cytokines by peripheral immune cells during inflammation, infection or trauma leads to release of pro-inflammatory cytokines by glia in the CNS; these cytokines are associated with induction and maintenance of pain 180 . Studies in animals and humans show that morphine induces secretion of pro-inflammatory cytokines by glial cells, leading to suppression of acute opioid analgesia, induction of tolerance after repeated opioid administration, development of opioid dependence and the seemingly paradoxical withdrawal-induced enhancement of pain 181 . Preoperative use of pentoxifylline, an inhibitor of cytokine production in immune cells, attenuated release of pro-inflammatory cytokines and reduced morphine consumption after surgery in patients with colorectal cancer 182 . The development of interventions that suppress opioidinduced activity of glial cells might promote better analgesia and enable more effective and safer use of these drugs. Cytokines and patient outcome Cytokines, drug toxicity and drug resistance. Most anticancer drugs are metabolized in the liver by cytochrome P450 (CYP) enzymes with the isoenzyme CYP3A4 being most important in this process 183 . Clinical studies have confirmed a relationship between pro-inflammatory cytokines and a systemic inflammatory response with increased levels of CRP, decreased activity of CYP enzymes 184, 185 and increased toxicity of chemotherapy 186 (FIG. 3) . However, the effect of the cancer on the inhibition of CYP enzymes was not studied. Recently, a mechanistic link between IL6 (which is associated with an acute-phase response induced by cancer growth) and impaired hepatic drug metabolism was demonstrated in a transgenic animal model that recreates most aspects of human CYP3A4 regulation 187 . Although increased levels of pro-inflammatory cytokines can cause impaired metabolism and clearance of anticancer drugs, they may also reduce the anticancer effectiveness of the drugs (FIG. 3) . Pro-inflammatory cytokines can lead to activation of NFκB (bOX 1), which enables survival of cancer cells and provides a mechanism by which they might become resistant to chemotherapy and radiotherapy. By contrast, inhibitors of NFκB can sensitize tumour cells to the apoptosis that is induced by chemotherapeutic agents 188 . For example, in human cell lines derived from hormone-refractory prostate cancer, higher activity of NFκB and increased production of IL6 were associated with decreased sensitivity to docetaxel, whereas an NFκB inhibitor decreased production of IL6 and reversed resistance to docetaxel. In the same study, increased circulating levels of IL6 before treatment correlated with less of a decrease in the circulating levels of prostate-specific antigen 189 . Clinical studies in other cancers have confirmed an association between circulating levels of IL6 and resistance to chemotherapy 190, 191 .
Prognostic value of cytokines. There is increasing evidence that the pattern and level of cytokine production is related to cancer prognosis. Genes associated with metastasis can be expressed in cancer and stromal cells in early-stage primary tumours [192] [193] [194] , and tumour infiltration by some innate immune cells, such as mast cells and macrophages, has been reported to be detrimental in different human cancers [195] [196] [197] [198] . Increased expression of the gene encoding CD68, a macrophage marker, was associated with poor prognosis when used as a part of a 21-gene signature (Oncotype DX) in breast cancer 199 . A gene expression signature of 17 mainly cytokineencoding genes isolated from non-cancerous liver tissue surrounding hepatocellular carcinoma, indicated that a switch from expression of T H 1 to T H 2 cytokines independently predicted tumour metastasis and recurrence 200 . Similarly, a 15-cytokine gene signature in non-cancerous lung tissue with a shift towards T H 2 cytokines predicted the involvement of regional lymph nodes in patients with adenocarcinoma of the lung, whereas a refined 11-cytokine gene signature from lung tumours and non-cancerous surrounding tissue independently predicted survival in early stage adenocarcinoma of the lung 201 . These findings support the hypotheses that cancer and stromal cells collaborate with surrounding uninvolved tissue in cancer development. Cytokine gene signatures of the non-cancerous surrounding tissue combined with gene signatures of the primary tumour can refine prognostic information for cancer recurrence and provide new insights into the biology of cancer.
The genes that encode IL1, IL6, TNFα and TGFβ are expressed in metastases from several cancer types, suggesting that common transcriptional programmes are activated during invasion 202 . There is evidence from animal models that risk of metastatic dissemination is dependent on the germline genetic background, which contrasts with the conventional model in which somatic mutations in cancer cells create a subpopulation of cells that disseminate 203 . In patients with early-stage colorectal cancer, high levels of IL6 secretion by peripheral blood mononuclear cells stimulated in vitro by LPS independently predicted for metastatic disease and impaired survival, although some healthy controls were also high producers of IL6 (ReF. 204) . These results suggest that host factors may have a major role in the progression of cancer.
IL6 is one of the most ubiquitously deregulated cytokines in cancer patients 205 and high levels of circulating IL6 most commonly predicted poor outcome in observational studies 23, 24, [206] [207] [208] (Table 2 ). Other data suggest that some specific cytokines and their receptors might have a predictive role for outcome in some cancer types 20, 22, 28 . Stage is an important prognostic factor in every cancer type and in observational studies there is a consistent trend of higher levels of circulating cytokines in more advanced stages of various cancers than in early stages 22, 24, 27, 206, [209] [210] [211] (Table 2) , which further supports an association with outcome of cancer.
Genetic polymorphisms of cytokines might also affect outcome (Table 3 ). In a study of patients with advanced renal cancer, the presence of the IL4 (-589 T, -33 T) haplo type, which is associated with increased expression of this T H 2 cytokine 212, 213 , was an independent prognostic factor for lower survival than that of patients that were homozygous for IL4 (-589 C, -33 C) 214 . However, the same IL4 haplotype (-589 T, -33 T) decreased susceptibility for the development of renal cancer 214 . Similarly, the ATA (-1082 A, -819 T, -592 A) haplotype of IL10, which is associated with low production of IL10, independently predicted increased survival in patients with advanced melanoma (but also increased susceptibility for the development of melanoma) 215 and T-cell non-Hodgkin lymphoma 216 . By contrast, the IL10 (-1082 G) allele, which results in increased secretion of IL10, independently predicted improved survival of patients with diffuse large B-cell lymphoma 217 . Thus, cytokines may have various roles in different stages of cancer and in different cancer types.
Diet, exercise and cytokine levels. Increasing evidence from observational studies indicates that better lifestyle, including moderately intense physical activity [218] [219] [220] [221] and lower fat intake 218, 222 , results in improved survival after treatment of patients with early breast and colon cancer. In women with breast cancer, beneficial effects of better lifestyle seem to be stronger in oestrogen receptor (ER)-positive disease [218] [219] [220] . By contrast, in the Women's Intervention Nutrition Study, a large randomized trial that investigated lifestyle intervention with reduced dietary fat intake, there was a decreased probability of breast cancer recurrence, especially in women with ER-negative breast cancers 223 , indicating involvement of mechanisms other than changes in female sex hormones. In the Million Women Study, higher body mass index was associated with an increased risk for 10 of 17 different cancers and the patterns for cancer mortality were broadly similar to those for cancer incidence 224 . The antiinflammatory effect of physical activity, and the attenuation of inflammation that results from lower fat content in the body, could explain the better outcome of cancer in these studies. A physically active lifestyle leads to reduced TLR4 signalling and decreased production of pro-inflammatory cytokines in non-cancer populations 142, 225 and has been reported to increase cytotoxic activity of NK cells in breast cancer survivors 226 . White adipose tissue is a source of various cytokines (that is, adipokines) with predominantly pro-inflammatory activity 227 . The increased production of cytokines by adipocytes and macrophages that infiltrate adipose tissue is reduced by physical activity and by a hypocalorific diet 228 . The effect of physical activity and other lifestyle interventions on cancer outcome might depend on genetically predetermined ability to produce cytokines and other mediators, such that only a subset of patients with cancer might benefit from such activity.
Concluding remarks
Pro-inflammatory cytokines are involved in the development and progression of cancer and are also associated with fatigue, depression, cognitive impairment, cachexia and anorexia, and pain, which affect quality of life. Sustained production of some cytokines may also be associated with cancer recurrence and progression. Strategies to inhibit the effects of such cytokines might therefore have a profound effect on quality of life and survival. Given the pleiotropic and redundant nature of cytokines, a successful approach might not involve inhibition of one particular cytokine but rather aim to shift the balance between pro-and anti-inflammatory cytokines. Increasing evidence suggests that, with its anti-inflammatory effects, physical activity might be an important part of treatment with the goals of prevention of fatigue and even prevention of cancer recurrence and death. There is a signal from candidate gene studies that polymorphisms in cytokine genes influence the susceptibility and course of cancer, and the symptoms related to cancer and its treatment.
